JUN and nonpapillary renal cell carcinoma: Consistently with what was hypothesized in a recent proteogenomics ccRCC study (Clark et al, 2020), we were able to capture crosstalks between members of the interferon gamma pathway (such as JUN), YY1 and metabolic down‐regulation observed in our data ((3) in Fig 4).